HIPRAY: H1710 completes the enrollment of the first subject in Phase I clinical trial and receives the first dose of the drug.

Announcement from Haiprui: The company's independently developed innovative candidate drug H1710 for injection has completed its first subject enrollment and first dosing in Phase I clinical trial. H1710 is a low anticoagulant heparin derivative, a highly efficient and selective acetyl heparinase inhibitor developed by Haiprui. This clinical trial is an open-label, dose-escalation phase Ia study, evaluating the safety, tolerability, and preliminary anti-tumor activity of H1710 in patients with advanced solid tumors. It is expected to enroll approximately 36 patients.